Weekly Digest – March 2025 Weekly Digest – March 2025 10 Mar 2025: Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) approved for marketing in second indication by NMPA for EGFRm NSCLC • Sichuan Kelun-Biotech’s TROP2-directed ADC, sac-TMT, is now approved in […]
Weekly Digest – March 2025 Weekly Digest – March 2025 12 Mar 2025: Zai Lab announces acceptance of biologics license application for TIVDAK for the treatment of patients with recurrent or metastatic Cervical cancer Zai Lab announced that China’s NMPA […]
Weekly Digest – March 2025 Weekly Digest – March 2025 13 Mar 2025: ImmunoPrecise teases $10M ADC, bispecific collab with major biotech ImmunoPrecise antibodies has partnered with a leading biotech company to develop antibody-drug conjugates and bispecific antibodies for cancer […]
Weekly Digest – March 2025 Weekly Digest – March 2025 13 Mar 2025: SOTIO Expands ADC Pipeline and Synaffix collaboration to develop two novel bispecific candidates, SOT112 and SOT113 SOTIO is exercising its option under the agreement with Synaffix to […]
Weekly Digest – March 2025 Weekly Digest – March 2025 11 Mar 2025: WuXi XDC and AbTis announce strategic partnership to advance next-generation ADCs WuXi XDC, a leading CRDMO in ADCs, signed an MOU with AbTis, a south Korean ADC […]
Weekly Digest – March 2025 Weekly Digest – March 2025 10 Mar 2025: Immunome doses first patient in Phase 1 trial of IM-1021, a ROR1-targeted ADC Immunome, Inc. has initiated the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC, […]
